Quantcast

Zoloft Birth Defect Lawyers Report Progress in Zoloft Litigation: Status Conference for Federal Zoloft Birth Defect Lawsuits to Convene on October 17

October 1, 2012

More than 152 Zoloft Lawsuits Pending in U.S District Court, Eastern District of Pennsylvania, Allege Zoloft Caused Birth Defects when Ingested by Pregnant Women.

Melville, NY (PRWEB) October 01, 2012

The Zoloft birth defect lawyers at Alonso Krangle LLP, a leading national law firm focused on fighting for the rights of serious personal injury victims, report that the federal litigation recently established for Zoloft birth defect lawsuits is moving forward, with the litigation´s next status conference scheduled for October 17, 2012. In an Order dated September 11, 2012, U.S. District Judge Cynthia Rufe, who is overseeing In Re: Zoloft (Sertraline Hydrochloride) Products Liability Litigation (MDL 2342) in the U.S. District Court, Eastern District of Pennsylvania, also set the schedule for the next four status conferences in the Zoloft MDL.

[//http://www.paed.uscourts.gov/documents/MDL/MDL2342/PTO10.pdf

The Zoloft birth defect lawyers at Alonso Krangle LLP continue to offer free Zoloft birth defect lawsuit evaluations to any family who believes their child´s suffering was the result of their mother´s use of Zoloft during pregnancy. Birth defects allegedly associated with Zoloft include:

To discuss a potential Zoloft birth defect lawsuit with one of the experienced and compassionate Zoloft birth defect lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.

Zoloft is an SSRI antidepressant marketed by Pfizer Inc. that was approved by the U.S. Food & Drug Administration (FDA) in 1991. Zoloft is used to treat major depression, obsessive-compulsive disorder, panic disorder, and anxiety disorders. Some 152 Zoloft birth lawsuits currently pending in the federal litigation in Pennsylvania allege that Zoloft can cause a variety of birth defects when the drug is taken by an expectant mother. The Zoloft litigation was established by the U.S. Judicial Panel on Multidistrict Litigation in an Order dated April 17, 2012. The litigation´s next status conference is scheduled for Wednesday, October 17, 2012, at 9:30 a.m. at the United States Courthouse in Philadelphia.

[//coop.jpml.uscourts.gov/Panel_Orders/MDL-2342-Initial_Transfer.pdf]

In an Order dated September 11, 2012, Judge Rufe established that subsequent conference in Zoloft litigation will be held on:

  •     November 19, 2012
  •     January 17, 2013
  •     February 25, 2013
  •     March 25, 2013

All of the conferences will begin at 10:00 a.m. at the United States Courthouse in Philadelphia. Judge Rufe´s Order stipulates that Lead Counsel submit a joint proposed

agenda no later than two weeks before each conference.

There is still time for families who believe their child´s birth defect was caused by Zoloft to file Zoloft birth defect lawsuits in this litigation. To discuss a potential claim with one of the experienced and compassionate Zoloft birth defect lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website at fightforvictims.com.

About Alonso Krangle LLP

Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. A national law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City and New Jersey.

For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.

Contact:

Alonso Krangle LLP

445 Broad Hollow Road

Suite 205

Melville, New York 11747

Toll-FREE 1-800-403-6191

Tel: 516-350-5555

Fax: 516-350-5554

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/10/prweb9953630.htm


Source: prweb



comments powered by Disqus